Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MLTX
MLTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MLTX News
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
3d ago
Fool
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
3d ago
NASDAQ.COM
BVF Partners Sells $62.96 Million in MoonLake Immunotherapeutics Shares
Apr 07 2026
Fool
BVF Sells 3.75 Million Shares of MoonLake Immunotherapeutics
Apr 07 2026
NASDAQ.COM
MoonLake's Clinical Trial Results Spark Interest
Mar 31 2026
stocktwits
MoonLake Immunotherapeutics Phase 3 Trial Results Show Promising Outcomes
Mar 30 2026
NASDAQ.COM
Escalating Middle East Tensions Impact Markets
Mar 30 2026
stocktwits
MLTX Stock Soars After Positive Phase 3 Results for Lead Skin Disease Treatment, Most Patients Show Improvement
Mar 30 2026
stocktwits
Rothschild & Co Upgrades MoonLake to Buy on Approval Path Clarity
Mar 19 2026
seekingalpha
Cormorant Asset Management Increases Stake in MoonLake Immunotherapeutics
Mar 17 2026
Fool
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
MoonLake Immunotherapeutics Receives Upgraded Rating
Feb 23 2026
Yahoo Finance
Vanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading
Feb 23 2026
Benzinga
Trump Announces Global Tariff Increase to 15%
Feb 23 2026
stocktwits
MoonLake's S-OLARIS Trial Data Shows Positive Results
Feb 23 2026
stocktwits
MoonLake's S-OLARIS Trial Results Show Significant Efficacy for Sonelokimab
Feb 22 2026
Newsfilter
Show More News
